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The East African region has a significant burden of communicable and non-
communicable diseases, yet patients have low access to essential medicines and 
medical supplies. Some of the barriers to accessing medicines are high prices and 
stock-outs. Pooled procurement of health products is an innovative approach to 
obtaining large volumes of products at competitive prices, thus promoting 
affordability and availability. A number of factors influence the success of pooled 
procurement mechanisms. These include sustainable financing, harmonization of 
processes and political support. The East African Pooled Procurement Mechanism 
had been in operation for over three years but significant benefits were not being 
realized. This study sought to understand how this pooled procurement 
intervention was implemented, challenges encountered and key strategies for the 
realization of intended outcomes.  A census survey was conducted among members 
of the pooled procurement steering committee. Data was collected through 
questionnaires, a focus group discussion and individual interviews. Collected data 
was analyzed using content and thematic analysis approaches. The results revealed 
that implementation of the East African pooled procurement intervention involved, 
for the most part, elements of successful implementation of pooled procurement 
mechanisms. These were stakeholder engagement; situation analysis; consensus 
building and implementation planning; setting up of a central procurement agency 
and managing and organizing procurement. However, a myriad of challenges were 
faced in the implementation of this intervention. The major ones were conflicting 
legislations and regulations for health products across the East African countries 
and limited financial resources for procuring health products and meeting 
administrative costs. As a result, there were marginal cost savings and delays in 
delivering or non-delivery of health products to medicine supply organizations. In 
view of the major challenges, it is recommended that the initiative adopts the third 
or fourth model of pooled procurement, to navigate country legislations and 
regulations for health products; a revolving drug fund for sustainable financing is 
implemented for organizations that are not financially stable and a continuous 
quality improvement system through reporting, monitoring and evaluation system 
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CHAPTER 1: INTRODUCTION  
  
1.1 Background to the Study 
The East African region, like the rest of Africa, has a high burden of human 
immunodeficiency virus and acquired immune deficiency syndrome 
(HIV/AIDS), tuberculosis (TB) and malaria. It also faces a significant burden of 
other communicable as well as non-communicable diseases. Access to essential 
medicines for managing these diseases is a key aspect in lowering this high 
disease burden. Access is defined as “having medicines continuously available 
and affordable at public or private health facilities or medicine outlets that are 
within one hour’s walk of the population” (UNDG, 2003). Essential medicines 
are those that satisfy the priority health care needs of the population. They are 
selected with due regard to public health relevance, evidence on efficacy and 
safety, and comparative cost-effectiveness. They are intended to be available 
within the context of functioning health systems at all times in adequate 
amounts, in the appropriate dosage forms, with assured quality and adequate 
information, and at a price the individual and the community can afford 
(WHO, 2018). According to one of the World Health Organization’s (WHO) six 
building blocks of a health system, “A well-functioning health system ensures 
equitable access to essential medical products, vaccines and technologies of 
assured quality, safety, efficacy and cost effectiveness, and their scientifically 
sound and cost-effective use”(WHO, 2010). 
 
Generally, access to essential medicines in developing countries is not 
adequate. In countries for which there is information, the availability of 
medicines in the public sector is only one third, while private sector 
availability is about two thirds, and the prices people pay for lowest-priced 
generic medicines vary from 2.5 times to 6.5 times international reference 
prices in these two sectors, respectively. Access to essential medicines can be 
improved through stronger partnership among governments, pharmaceutical 
companies and civil society, including consumers, working together to ensure 




Patients in East Africa partner countries have low purchasing power and 
cannot easily afford to buy medicines. Government budgets are also 
insufficient to meet healthcare needs. In Kenya, for instance household out-of-
pocket (OOP) healthcare financing accounted for 28% of the total healthcare 
financing mechanisms between the financial years 2009/2010 to 2015/2016 
(MOH, 2017). This compromises equitable access to essential health products 
and makes the healthcare market extremely price-sensitive.  
 
1.2 Pooled Procurement Mechanism 
Pooled procurement is purchasing done by one procurement office on behalf 
of a group of organizations, facilities, health systems or countries (Ghoneim, 
Mpundu & Mabirizi, 2016). Participating members agree to purchase certain 
medicines exclusively through this mechanism (Syam, 2014). Pooled 
procurement activities are aimed at improving the outcomes of procurement 
for individual members. Successfully implemented regional pooled 
procurement mechanisms (PPMs) help countries access sustainable supply of 
quality essential medicines, achieve greater demand predictability and reduce 
transaction costs (WHO, 2017). Besides, economies of scale result in better 
leverage in pricing negotiations with pharmaceutical companies leading to 
significant price discounts. A regional PPM could also attract major medicines 
suppliers by offering a large regional market compared to smaller national 
markets (UN, 2005). It is also noted that PPM can lead to elimination of 
wasteful expenditure, unnecessary purchase and stock outs. The 
implementation of regional PPMs is influenced by a myriad of factors 
including sustainable financing, harmonization of processes and political 
support among others.  
 
Reduce transaction and health product costs, increase availability and 
continuous supply and enhance streamlined and efficient procurement 
management systems (WHO, 2017). 
 
1.3 Levels of Pooled Procurement 
The WHO outlines four levels of pooled procurement. Each level represents an 
individual mechanism on its own or a step in the process of attaining higher 
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levels of cooperation. The four levels are informed buying, coordinated 
informed buying, group contracting and central contracting. In the first level, 
member countries share information, particularly about suppliers and 
products and procurement is conducted individually. In the second level, 
coordinated informed buying, member countries undertake joint market 
research, share supplier performance information and monitor prices. 
Procurement is also conducted individually. In the third level, known as group 
contracting, member countries jointly negotiate prices, select suppliers and 
purchase from the selected suppliers. Procurement is conducted individually. 
Under central contracting, member countries jointly conduct tenders and 
award contracts through organizations acting on their behalf. The central 
buying unit manages purchases on behalf of member countries.  
 
Figure 1.1 Levels of Pooled Procurement 
1.4 Problem Definition 
Four faith-based medicines supply organizations (MSOs) in East Africa, Mission for 
Essential Drugs and Supplies (MEDS), Kenya; Bureau des Formations Médicales 
Agréent du Rwanda (BUFMAR); Mission for Essential Medical Supplies, (MEMS), 
Tanzania and Joint Medical Store (JMS), Uganda formed a partnership in the year 
2010 to increase the affordability and availability of quality assured essential 
medicines in the East African region. This was to be achieved through joint bulk 
purchasing or pooled procurement of medicines and medical supplies. Ecumenical 
Pharmaceutical Network (EPN) was appointed as the secretariat of this 
partnership. EPN is a Kenyan-based, non-governmental organization whose 
mission is to promote the provision of just and compassionate quality 




Two joint bulk purchasing exercises were conducted in 2015 and 2016 respectively, 
but were characterized by minimal price reductions, inconsistent supply of health 
products and administrative challenges. These and other undocumented challenges 
had largely contributed to the East African pooled procurement mechanism’s 
(EAPPM) failure to achieve meaningful impact years after formation. Worse still, no 
systematic research, analyses and documentation of experiences and challenges had 
been done, making it difficult for member organizations to make informed 
decisions on the best way forward. 
 
This study seeks to understand how the pooled procurement intervention was 
implemented and challenges encountered, if any. The findings will inform member 
organizations on the best way forward and contribute, globally, to the debates 
around the uptake and implementation of pooled procurement models as an 
intervention to increase affordability and availability of quality assured medicines.  
 
1.5 Research Objectives 
1.5.1 Primary objective 
To assess how the East African pooled procurement mechanism of faith-
based medicines supply organizations was implemented. 
1.5.2 Specific objectives 
a) To determine if stakeholders were engaged in the implementation 
of the EAPPM intervention. 
b) To determine if a situation analysis was conducted in the 
implementation of the EAPPM intervention. 
c) To find out if an EAPPM implementation plan was mutually 
developed by stakeholders. 
d) To find out if a central procurement agency or secretariat was 
established in the implementation of the EAPPM intervention. 
e) To establish how procurement of products was managed in the 







1.6 Research Questions  
a) Were stakeholders engaged in the implementation of the EAPPM 
intervention? 
b) Was a situation analysis conducted in the implementation of the EAPPM? 
c) Was an EAPPM implementation plan mutually developed by 
stakeholders? 
d) Was a central procurement agency or secretariat established in the 
implementation of the EAPPM? 
e) How was procurement of products managed in the implementation of 
the EAPPM intervention? 
 
1.7 Scope of Study 
The study involved all the eighteen members of the EAPPM steering 
committee that had been involved in actualizing it since inception. The steering 
committee was composed of two teams namely, Chief Executives Committee 
(CEC) and Technical Working Group (TWG). The CEC was composed of Chief 
Executive Officers of the four MSOs and the Executive Director of EPN. The 
TWG consisted of representatives of each MSO and EPN. The study 
specifically gathered data on how the EAPPM was established and challenges 
encountered during implementation. 
 
1.8 Significance of Study 
Pooled procurement mechanisms are an intervention to, primarily; exert 
downward pressure on the prices of essential medicines thus increasing their 
affordability (Veronika et al, 2016). They also assure consistent supply of heath 
products thus eliminating stock outs. The results of this study will guide 
appropriate action to be taken so that the goal of price reductions and 
continuous availability of health products is realized to the benefit of patients. 
Increased affordability and availability of health products in the respective 
countries will instill public confidence in their health systems and increase 
uptake of public health services. Ultimately, increased access to essential 





CHAPTER 2: LITERATURE REVIEW 
 
2.1 Introduction 
This chapter discusses descriptions of key terms, a theoretical literature review, 
an empirical literature review and a conceptual framework. The theoretical 
literature review discusses the stakeholder theory in relation to establishing a 
PPM for health products. The components of establishing a PPM are 
engagement of stakeholders; situation analysis; consensus building and 
implementation planning; setting up a central procurement agency (CPA), and 
managing and organizing procurement.  In each of these components, an 
examination of the application of the stakeholder theory is discussed. The 
empirical literature review discusses regional multi-country PPMs of 
medicines in various parts of the world. These are African Association of 
Central Medical Stores for Essential Drugs (ACAME); Revolving Fund for 
Essential Drugs for Central America and Panama (FORMED); Gulf 
Cooperation Council/Group Purchasing Programme (GCC/GPP) and 
Organization of Eastern Caribbean States (OECS/PPS)/Pharmaceutical 
Procurement Service. The chapter finally discusses a conceptual framework for 
implementing the EAPPM.  
 
2.2 Descriptions of Key Terms 
2.2.1 Stakeholder engagement 
The bringing together organization entities, resources and participants to 
optimize value and efficiency in developing and building a streamlined 
and effective pooled procurement system. 
 
2.2.2 Situation analysis 
An assessment of the capacity at the individual and organizational levels 
to manage and conduct a well-performing procurement system with the 







2.3 Theoretical Framework 
This theoretical framework examines the stakeholder theory in light of the 
implementation of a PPM. 
2.3.1 Stakeholders 
Stakeholders are defined as individuals, groups and organizations that 
have an interest in the processes and outcomes of a firm and upon whom 
the firm depends for the achievement of its goals (Freeman, 1984; 
Freeman, Harrison & Wicks, 2007). Stakeholders can be differentiated as 
either internal or external, and primary or secondary. Those stakeholders 
within a firm, i.e. employees, managers, and owners are depicted internal 
stakeholders, while those outside of an organization, e.g. suppliers, 
customers, and the government, are defined as external stakeholders. 
Primary stakeholders are crucial to an entity’s survival, while secondary 
stakeholders have no formal claim on a firm; firms merely endeavour not 
to do them any harm (Parmar et al., 2010). The internal stakeholders in 
the EAPPM were board members, CEOs and TWG members of MSOs 
and EPN. External stakeholders were suppliers, patients, the community 
and governments of the various countries involved in the EAPPM.  
 
2.3.2 Stakeholder theory 
According to Freeman et al. (2010), stakeholder theory aims at improving 
the understanding of value creation and how it is traded, connecting 
ethics and capitalism, and helps managers deal with these matters 
(Freeman et al., 1997; Parmar et al., 2010). In other words, the stakeholder 
theory addresses the problem of value creation and trade, the problem of 
ethics of capitalism, and the problem of managerial mindset (Parmar et 
al. 2010). Donaldson and Preston (1995), argue that the different facets of 
the stakeholder theory are descriptive accuracy, instrumental power and 
normative validity.  Stakeholder theory is descriptive in the sense that “it 
describes the corporation as a constellation of cooperative and 
competitive interests possessing intrinsic value”, it is instrumental 
because “it establishes a framework for examining the connections, if 
any, between the practice of stakeholder management and the 
achievement of various corporate performance goals” and finally “the 
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fundamental basis” of stakeholder theory is normative and involves 
acceptance of the following ideas: “stakeholders are persons or groups 
with legitimate interests in procedural and /or substantive aspects of 
corporate activity” and “the interests of all stakeholders are of intrinsic 
value”. 
 
Figure 2.1. The stakeholder theory model 
 
2.3.3 Stakeholder theory in the pooled procurement mechanism 
a) Normative validity 
Stakeholders are persons or groups with legitimate interests in 
procedural and /or substantive aspects of corporate activity. The 
interests of all stakeholders are of intrinsic value. The concept of 
establishing a PPM has this theory in play because the intrinsic 
value of stakeholders is an incentive for them to be part of the PPM. 
They all indeed have legitimate interests in substantive aspects of a 
PPM.  
 
b) Instrumental power 
Setting up a CPA and managing and organizing procurement in a 
PPM are best described by this aspect of the stakeholder theory. The 
CPA and its role in managing and organizing procurement 
establish the connection between stakeholders, their management 
and the achievement of the pooled procurement goals.  
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c) Descriptive accuracy  
Engaging stakeholders with the aim of developing and building a 
streamlined and effective pooled procurement system, conducting a 
situation analysis and mutual development of a strategic and 
implementation plan describe the theory of a constellation of 
cooperative and competitive interests that are exploring value 
creation and how to trade it in exchange for value. 
 
2.4 Empirical Literature Review  
2.4.1 African Association of Central Medical Stores for Essential Drugs 
ACAME was a regional multi-country pooled procurement mechanism 
that was established in 1996. It adopted the group contracting level of 
pooled of procurement and piloted its first joint bid purchase in 1998.  
a) Stakeholder engagement 
Stakeholders held a general assembly at the inception of ACAME 
with 11 countries in attendance. These were Benin, Burkina Faso, 
Chad, Democratic Republic of the Congo, Guinea, Madagascar, 
Mali, Niger, Rwanda, Senegal and Togo. The assembly decided to 
conduct a joint bulk-purchasing test with a group of countries and 
to report to the general assembly in September 1998 in Bamako, 
Mali. The countries involved in the initial pilot were Guinea, Mali 
and Niger. The objectives of ACAME were to promote the 
establishment of central medical stores (CMS) for generic essential 
drugs in African countries which do not have them; to set up a data 
bank on suppliers and prices; to promote the exchange of 
information among CMS for generic essential drugs; to 
progressively organize joint bulk purchasing and to protect the 
moral and material interests of members. 
 
b) Situation analysis 
Whilst there is no evidence of a systematic and detailed assessment 
of the gaps necessitating establishment of ACAME, it is noted that 
the devaluation of the CFA franc had resulted in a sharp increase in 
the prices of essential medicines that affected their affordability and 
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availability. It was also felt that there was need to strengthen drug 
and pharmacy management in the region.  
 
c) Consensus building and implementation planning 
The group contract level of pooled procurement and categories of 
products for the bulk purchase were agreed upon. These were “fast-
moving” and “slow-moving” generic oral and parenteral 
pharmaceutical products. Center for Pharmaceutical Management, 
(2002) cites that “an agreement clearly defining the applicable rules 
during the entire tender period must be prepared and signed; this 
agreement must cover all matters concerning drug marketing; and 
the framework agreement should be transparent to reassure 
suppliers”. Besides, signing a framework agreement governing the 
joint bulk purchasing process and procedures was an area that had 
been omitted (CPM, 2002).  
 
d) Central procurement agency 
For the test joint bulk purchasing, Pharmacie Populaire du Mali was 
responsible for coordinating the activity because a permanent 
secretariat had not yet been established. One of the lessons learnt at 
the end of the pilot was that establishing a permanent secretariat to 
act as a data bank that disseminates information to all member 
countries was crucial for the success of a pooled procurement 
mechanism.  
 
e) Managing and organizing procurement 
ACAME had a tender committee composed of procurement 
managers of member CMSs. It adopted restricted tendering and a 
shortlist of 25 suppliers was established from the list of best 
suppliers of each member’s CMS, and a shortlist of five anti-
infective drugs (from the countries’ essential medicines list) was 
selected. The committee established bidding conditions and 
adjudicated the tendering process. Products were delivered to 
individual purchasers since they had signed separate contracts with 
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the selected suppliers. The supplier was thus paid directly by each 
participating country, 30 percent upon delivery of goods and 70 
percent after quality control testing. 
 
ACAME did not receive any external technical assistance. WHO did 
provide a grant of USD 4,000 to ACAME at the outset, and two 
meetings received partial financial support from West African 
Economic and Monetary Union (UEMOA) and other donors. 
 
The Niamey Laboratory in Niger (the regional quality control 
laboratory) was selected to conduct drug quality control testing. 
However, for communication and cost reasons, the Laboratoire 




ACAME’s pilot achieved price reductions with five anti-infective 
medicines. The prices obtained were 7 to 27 percent lower than the 
lowest prices each of the participating countries had obtained for 
more than three years for any of the five medicines. Additional 
benefits noted were that group bulk purchasing reduced expenses 
through regional quality control and that it enhanced information 
exchange about providers and pharmaceutical manufacturers 
(Centre for Pharmaceutical Management, 2002). 
 
g) Challenges 
Political instability in the region and lack of transparency in 
carrying out analyses and inviting tenders existed (ACAME and 
WHO/AFRO 1999b). There were delays in deliveries and ACAME 
noted that this was to be a disincentive for awarding contracts. 
There was registration of products challenges and as a result, 
countries were encouraged to harmonize registration procedures in 




Guinea did not have the CFA franc as its national currency, had 
difficulties with the mode of payment suggested by the schedule of 
conditions. Suppliers did not comply with coverage of insurance 
expenses in accordance with the tender agreements, which caused 
difficulties for countries with less experience in dealing with these 
types of transactions. 
 
The tender documents did not adequately clarify controlling rules 
when regulations in the various countries differed, especially in the 
area of drug registration. 
 
g) Lessons learnt 
ACAME learnt that firm commitment and will of the CMS 
managers, backed by the support of their ministers of health was 
imperative.  
 
2.4.3 Revolving Fund for Essential Drugs for Central America and Panama 
FORMED is a drug revolving fund that was established in Central 
America in 1986 for the purchase of pharmaceuticals. Its objectives were 
reduction in the prices of pharmaceuticals; encouraging joint actions 
between countries of the sub-region in response to common problems, 
thus promoting a Central American spirit of cooperation; improving 
intersectoral coordination and management of the purchasing process; 
helping promote participation by the Central and Latin American 
pharmaceutical industry in the purchases made by the countries. It 
operated for about three to four years and ended around 1989, after two 
rounds of joint purchases. 
a) Stakeholder engagement 
There were seven countries involved namely Belize, Costa Rica, El 
Salvador, Guatemala, Honduras, Nicaragua and Panama. There 
was however no formal, legally binding agreement made among 
the countries. Political commitments were expressed in the form of 




b) Situation analysis 
An analysis conducted by the Pan American Health Organization 
(PAHO) confirmed that prices paid by governments not only varied 
greatly from country to country but were also considerably higher 
than prices obtained through PAHO or United Nations Children’s 
Fund (UNICEF) (Center for Pharmaceutical Management, 2002). 
 
c) Consensus building and implementation planning 
In the initial phase of the project, 16 essential drugs were selected 
on the basis of the following criteria - basic medicines used to treat 
diseases prevalent in the population; medicines part of specific 
health care programs for the control of such priority health 
problems as acute respiratory infections, parasitic diseases, diarrhea 
and dehydration, malaria and tuberculosis, single medicines of 
good quality and recognized effectiveness; medicines whose 
purchase represent sizeable public sector expenditure or 
consumption and utilization of foreign exchange, medicines listed 
in the latest report of the WHO Expert Committee on Essential 
Drugs, medicines difficult to obtain, medicines whose procurement 
would have a considerable economic impact on the participating 
institutions and whose joint purchasing would bring about 
considerable savings. 
 
d) Central procurement agency 
PAHO acted as the secretariat. A manual of guidelines and 
procedures for FORMED was prepared by PAHO and was 
subsequently reviewed and approved by national coordinators 
designated by the participating countries. All purchases were made 
through the PAHO procurement office. Using the concept of a drug 
revolving fund, member countries were to make monthly payments 
to PAHO in hard currency i.e., United States of America (US) 





e) Managing and organizing procurement 
Orders were placed by member states’ CMSs, through the local 
PAHO office in the country, to the PAHO procurement office in 
Washington, DC. The procurement office, in turn, solicited 
international competitive bids (ICB) and purchased the drugs from 
the supplier with the lowest bid. The lead time was originally set at 
four months, which in reality became five to seven months (and 
more than a year in one case when the orders were misfiled) 
(Rankin 1991b). FORMED began with purchases of commonly used 
and easily procured essential medicines (a list of 16 drugs) and raw 
materials, but later included purchases of expensive essential 
medicines. The first round of joint purchases amounted to USD 3.3 
million (including USD 0.68 million for raw materials); 139 
suppliers were contacted, 33 bids were received, and 12 bids were 
awarded. The second round of joint purchases amounted to 
approximately USD 1 million. 
 
FORMED was one of several projects on essential drugs funded by 
various agencies through PAHO. It was initially capitalized with a 
donation from the Dutch government of USD 4 million. The 
Swedish government also provided USD 277,000 during the first 
year to finance the technical cooperation necessary to implement 
the program.  
 
The PAHO secretariat did not receive technical assistance to 
establish FORMED. Rather, it provided the technical assistance and 
managed the procurement program as part of the activities of its 
Essential Drugs Program and the procurement office, both at 
headquarters and in the field. 
 
f) Achievements 
Reduction in prices averaged 64 percent, ranging from 26 percent 
(Costa Rica) to 75 percent (Guatemala), depending on 
administrative efficiency and negotiating capacities of the different 
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procurement systems in the sub-region. The price reductions were 
attributed to international competitive bidding; prompt payment in 
US dollars, purchases packaged in economical units, large volume 
of purchases and selection of the most economical method of 
transportation. In addition, pharmaceutical price information 
system was generated and a mutual regional essential medicines list 
was established. 
 
Despite FORMED’s discontinuation, Belize continued to participate 
in a drug revolving fund arrangement with PAHO for some time 
because it continued to obtain better prices through PAHO. 
However, in 1990, the Government of Belize began to have 
difficulty making monthly payments to the revolving fund, and it is 




Completion of the second round of purchases was threatened by 
the failure of some of the participating countries to settle their 
obligations from the first round. Lack of payment to the revolving 
fund was attributed as the main reason for FORMED’s failure. The 
donor-funded revolving fund absorbed the costs that were not 
reimbursed, which drained the fund account. Secondly, the 
countries’ supply of hard currency was limited, especially during 
the 1980s; that priority for available hard currency was given to 
other areas, such as vaccine procurement. Thirdly, reimbursements 
to the fund were not legally or strictly enforced before the next 
order was placed; and there was no strong central authority (such 
as a regional bank) to ensure that financing mechanisms were 
sound and adequately enforced. Fourthly, ministries of health were 
lax in making the prescribed contributions to the revolving fund 
(Rankin 1991b) and fifthly, resistance was encountered at country 
level in the local procurement offices. Local suppliers undermined 
the program by offering inducements to procure locally rather than 
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through FORMED. The result was that a substantial portion of the 
funds that should have been used to replenish FORMED accounts 
was instead used to purchase products on the local market (Rankin 
1991b). 
 
Another challenge encountered was poor procurement 
management on the part of PAHO headquarters, PAHO local 
offices, and the member countries’ CMSs (for example inefficient 
communication between the parties involved). Operational 
challenges met included delays caused by long delivery times 
(which made planning difficult and necessitated emergency 
purchases), slow customs clearances, unacceptable expiration dates, 
inadequate external packaging, wrong language on the labels, 
delays in receiving analysis results from reference laboratories and 
incorrect shipping documents. 
 
2.4.4 Gulf Cooperation Council / Group Purchasing Programme 
GCC/GPP began in 1976 and continues to date. Its objectives were 
securing financial surplus through purchasing; large amounts of supplies 
for a smaller price; certifying companies that follow good manufacturing 
practices and that are registered according to the rules and regulations 
set by the Executive Board, thus ensuring a high quality of purchased 
items; ensuring use of the same drugs manufactured by the same 
company by all the GCC states; rapid processing and awarding of 
presented tenders; ensuring a continuously supply of drugs, hospital 
supplies and equipment all year round through regular successive 
deliveries; encouraging other health sectors, e.g. specialized hospitals, to 
secure their needs through group purchasing; encouraging the policy of 
purchasing from generic-registered companies to obtain a greater 
financial surplus and supporting the Gulf drug industry to achieve 
security of drug supplies in the Gulf countries (Khoja & Bawazir, 2005). 
a) Stakeholders engagement 
Following the first meeting of the Health Ministers’ Council (HMC) 
of the Arab Countries in the Gulf, a special division was created 
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within the HMC to oversee the group purchasing programme. 
Countries represented at the meeting were Bahrain, Kuwait, Oman, 
Qatar, Saudi Arabia and the United                                                                                  
Arab Emirates. 
 
b) Situation analysis 
Whilst there is no evidence that a structured situation analysis was 
conducted to elicit the gaps necessitating establishment of the 
group purchasing programme, the objectives cited give an 
indication that indeed certain gaps existed.  
 
c) Consensus building and implementation planning 
The GCC tender procedure is conducted through a committee 
composed of two representatives of the pharmaceutical sector from 
each member state and a delegate of the GCC executive bureau 
(Executive Office for Health Ministers) responsible for the entire 
procedure. 
 
d) Central procurement agency 
Following the first successful bid on pharmaceuticals in 1978, a 
permanent designated health committee within the GCC was 
formed (Executive Board HMC, 2002). A permanent secretariat was 
established by the ministers of health to conduct purchasing 
operations and act as a data bank. Its mandate was to procure safe 
and effective pharmaceutical products, hospital supplies, and 
equipment of high quality. 
 
e) Managing and organizing procurement 
The group purchasing committee meets at four decisive stages of 
the process: pre-tender preparations, bid opening, adjudication, and 
post-tender evaluation. Their work process involves reviewing 
submission of tenders from bidding companies; notification of 
countries about awards and sending samples of items awarded to 
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each country for delivery; notification of the companies about items 
awarded and the total sum of delivery (Khoja et al, 2005). 
 
The GCC invited only registered suppliers to the tender. The first 
tender in 1978 was for more than USD 1 million dollars and 
involved 32 items awarded to nine companies. By 2001, there were 
23 tenders for pharmaceuticals worth USD 234.5 million, involving 
1,127 items procured from 109 companies. Payments are made 
directly to suppliers through their local agents in U.S. dollars, 
except in Saudi Arabia and Kuwait, where local currency is used. 
At least 80 percent of the public sector drug needs of the member 
countries are met by group purchasing. Saudi Arabia buys all of its 
drugs through the group. Through group purchasing, an average of 
30 percent reduction in costs has been realized. Private hospitals 
have recently joined the bulk-purchasing system. The success of the 
group purchasing of pharmaceuticals has led the GCC to use bulk 
purchasing for hospital supplies, vaccines and sera, pharmaceutical 
chemicals (raw materials), medical rehabilitation supplies, and 
laboratory apparatus. 
 
Technical assistance from an outside agency was not provided 
during the planning of the regional pooled procurement program. 
Later, however, a consultation committee was appointed and 
worked closely with the program. This committee consisted mainly 
of faculty members from the College of Pharmacy at King Saud 
University and a pharmacist from the medical supply department 
of Saudi Arabia’s Ministry of Health. 
 
f) Achievements 
The achievements of GCC have been reduction in the costs of 
pharmaceuticals; reduction in operation costs; standardization of 
product use (using the same drugs by the same manufacturing 
companies) and product quality (purchasing only from companies 
registered according to the rules and regulations set by the 
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Executive Board, thus ensuring items of high quality); sharing of 
information among member states; enhanced purchase operations 
(ensuring rapid processing of presenting tenders and their awards);  
continuous supply of drugs, hospital supplies, and equipment year-
round through successive deliveries and minimizing routine 
administrative and financial procedures; improving the application 
of quality assurance, control procedures, and bioequivalence testing 
and expanding bulk purchasing to other health sectors, such as 
specialized hospitals. Other benefits include establishing a central 
drug registration, bioequivalence program, drug formulary, good 
manufacturing practices, and accreditation of central laboratories 
for quality control; the system has required solid defense against 
pressure of various types (Bawazir 2002). 
 
g) Challenges 
GCC was not devoid of challenges. There was decreased rate of 
participation by some member countries. Some countries did not 
purchase all the quantities they required through the programme 
which led to decreasing purchasing power; some members 
decreased the amount of their original quantities substantially after 
the tender award; some members delayed their notification 
regarding their final quantities that resulted in delays in the tender 
award; many companies offer reduced prices for their products in 
local tenders of some member countries with the intention of 
keeping these countries out of the programme and finally, some 
member countries did not participate in all tenders offered by the 
programme (Khoja et al, 2005). 
 
h) Lessons learnt 
The successes realized with the GCC/GCP were attributed to 
strong political commitment at ministerial level from the outset; 
standardization of registration procedures; independent, well-run 
executive secretariat and detailed description and follow-through 
with procedures, technical specifications, and the tendering process; 
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demand for local pharmaceutical production has been on the 
increase; registration procedures for drugs have improved; correct 
information and transparency are important; purchases of this size 
and at this level are always subject to attempts at interference from 
commercial and other pressure groups. 
 
2.4.5 Organization of Eastern Caribbean States  /  Pharmaceutical 
Procurement Service 
The OECS/PPS was created in 1981, with the mission of contributing to 
the sustainable development of its member states.  
a) Stakeholder engagement 
The nine member states of OECS - Anguilla, Antigua and Barbuda, 
British Virgin Islands, Dominica, Grenada, Montserrat, St. Kitts and 
Nevis, St. Lucia, and St. Vincent and the Grenadines were involved 
in the initiation of this bulk purchasing programme. In carrying out 
its mission, OECS works with a number of sub-regional and 
regional agencies and institutions, including the Eastern Caribbean 
Central Bank (ECCB), the Caribbean Community (CARICOM), and 
the Caribbean Development Bank. 
 
b) Situation analysis 
In 1986, the rising cost of pharmaceuticals led the OECS to establish 
the Eastern Caribbean Drug Service (now known as OECS/PPS). 
 
c) Central procurement agency / Secretariat  
The OECS secretariat and the OECS/PPS permanent secretariat are 
both located in Castries, St. Lucia. 
 
d) Managing and organizing procurement 
The program operates through a centralized, restricted tendering 
system and invites only prequalified suppliers to the international 
competitive bidding process. The member states procure about 85 
percent of their public sector pharmaceutical needs through this 
program. Pharmaceuticals are now purchased on the basis of the 
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biennial Regional Formulary and Therapeutics Manual. This 
manual consists of the core list of essential drugs common to all 
nine member states; it has reduced wastage resulting from 
overstocks and nonessential items. 
 
Technical assistance was provided by Management Sciences for 
Health (MSH) from 1986 to 1990, through the U.S. Agency for 
International Development (USAID) with an initial amount of USD 
3.5 million for technical assistance and start-up financing. Each 
country’s counterpart fund was XCD 0.7 million (approximately 
USD 260,000). 
 
Through USAID, MSH provided technical assistance to Eastern 
Caribbean Drug Service (ECDS) from July 1986 to September 1990 
(Rankin 1991a). Initially, USD 3.5 million was provided for technical 
assistance and start-up financing, while the countries’ counterpart 
fund was XCD 0.7 million (Burnett 2002a). ECDS became self-
sustaining in 1989, and in June of that year the Agreement 
Establishing the Eastern Caribbean Drug Service was signed by 
government representatives of each member state (OECS 1990). 
 
e) Achievements 
During the first year of the program’s operation (1987–88), 
participating countries benefited from an average 44 percent 
reduction in acquisition price (of the top 25 pharmaceuticals in the 
region), which has been sustained in subsequent tenders. Other 
achievements included comprehensive quality assurance program, 
including prequalification of selected suppliers; contractual 
purchasing agreements; regular testing of priority drugs; review of 
suppliers’ past performance; biennial regional formulary and 
therapeutics manual; provision to member states of related services, 
such as training and technical assistance, drug utilization studies, 
rational drug use guidelines, and inventory management. 
Availability of essential medicines has consistently been higher than 
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85% from 2010 (Regional workshop, 2014). Major reductions in unit 
prices of medicines, for example, prices more than 25% lower than 
individual country prices in the Organization of Eastern Caribbean 
States (OECS) (Burnett 2001). 
 
f) Challenges 
The reputation for prompt payment that OECS/PPS established 
initially was tarnished over the years because some countries were 
slow in reimbursing the country drug accounts due to economic 
challenges. Late payments resulted in several suppliers withholding 
shipments to both defaulting and non-defaulting countries. 
 
g) Lessons learnt 
An important element in OECS/PPS’s initial success in reducing the 
cost of pharmaceuticals was the ability to pay suppliers promptly in 
foreign exchange within 42 days (later changed to 60 days) of 
receipt of goods at country level. Bids are solicited in U.S. dollars 
(the exchange rate between the EC dollar and the U.S. dollar has 
remained stable for the last 25 years). The program enjoys strong 
political support of the member countries’ governments, and 
procurement activities are well run by the permanent secretariat. 
 
From this literature review, pooled procurement initiatives have 
existed for more than 30 years. Regional approaches to multi-
country PPMs have had mixed results, although there are long 
standing ones that have achieved great success e.g. GCC/GPP and 
OECS/PPS. It is worth noting that only one PPM has been 
successful in sub-Saharan Africa although the success was short 
lived. The benefits of PPMs are evident and seem to be similar 
across regions, globally. Some of these are drug costs savings, 
standardization of quality assurance and consistent supply of 
medicines among others. Likewise the common challenges 
encountered include defaulting countries, negative influence of 
local suppliers by offering lower prices than pooled procurement 
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prices and late payments to suppliers. Literature on regional multi-
country PPMs of medicines that does not involve state actors is 
lacking. The EAPPM does not involve the public health system and 
exclusively involves faith-based medicine supply organizations 
(MSOs).  
 
2.5 Conceptual framework 
In conducting this study, a conceptual framework was developed to show the 
relationship between independent variables and the dependent variable. In 
this study, the dependent variable is effective implementation of pooled 
procurement and the independent variables are; stakeholder engagement; 
situation analysis; consensus building and implementation planning; 
establishing a central procurement agency and managing and organizing 
procurement. The constructs and relationships between research variables are 
illustrated in the following figure 2.2.              
2.5.2 Stakeholder engagement 
Engagement of stakeholders is crucial in developing and building a 
streamlined and effective pooled procurement system. The essence of 
pooled procurement is about bringing together different organization 
entities, resources and participants to optimize value and efficiency in the 
pharmaceutical supply chain. Stakeholders are to be identified correctly 
and should meet and engage often and regularly, building the rapport 
and trust to continuously improve processes and systems in a 
coordinated and transparent manner. Engaging stakeholders includes 
identifying key stakeholders through stakeholder mapping; informing 
stakeholders of the option to develop a pooled procurement system; 
determining objectives, benefits, and primary concerns for collaboration 
in pooled procurement; establishing strategy and plans for procurement 
and a TWG based on key stakeholders’ feedback and establishing a 










                                      









               
 
                                                                                         
 






Figure 2.2.3 Conceptual Framework 
 
2.5.3 Situation analysis 
The importance of a situation analysis is that it ensures all stakeholders 
are in agreement about what the current issues and performance gaps are 
in terms of procurement and availability of essential medicines. The 
situational analysis can be based on previous studies conducted in the 
country or more specific, detailed and updated assessment on the 
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procurement related gaps (United Nations Children’s Fund, 2016) and 
associated costs; availability of essential medicines; financing for 
products, human resource and quality of products as part of the pooled 
procurement intervention (Ghoneim et al, 2016).  These inform the gaps 
and needs the pooled procurement intervention is to address. In the 
review of empirical literature gaps identified that necessitated the 
introduction of pooled procurement programmes were drastic increase in 
the prices of essential medicines that affected their affordability and 
availability; the need to strengthen drug and pharmacy management 
processes; enhancing quality of products and guaranteeing continuous 
supply of products.  
 
2.5.4 Consensus building and implementation planning 
Consensus building and implementation planning or mutual 
development of an implementation plan is the process of seeking 
unanimous agreement by stakeholders. In terms of establishing a pooled 
procurement programme, some of the areas that need mutual agreement 
with subsequent implementation planning are the central procurement 
agency and its scope of work, technical working group’s scope of work, 
selection of medicines, quantification procedures, potential suppliers and 
agreements on criteria, tendering process, ordering process, applicable 
incoterms, procedures and agreements for distribution and financial 
agreements and payment mechanisms (Ghoneim et al, 2016).  In the 
review of empirical literature, some of the areas where consensus was 
built in terms of the implementation plan were the list of products to be 
purchased, criteria for selecting medicines to be included in the bulk 
purchasing programme, level or model of pooled procurement to be 
adopted and purchasing processes and procedures. These parameters 
have a bearing on the extent of price reductions achieved in pooled 
procurement mechanisms.  
 
2.5.5 A central procurement agency 
Stakeholders agree on the overall mandate of a CPA or secretariat and 
establish it. Some considerations in setting up the CPA are selecting 
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procurement methods, establishing roles and responsibilities of the CPA 
and developing standard operating procedures around receipt, 
inspection, customs clearance, storage, distribution and transport. The 
success of GCC was attributed to a well run secretariat among others. A 
CPA or secretariat for group contracting or central contracting model of 
pooled procurement is thus important, if pooled procurement 
intervention goals are to be achieved.  
 
2.5.6 Managing and organizing procurement 
The procurement agency or secretariat plays a vital role in managing and 
organizing the procurement process. The processes of the CPA revolve 
around ensuring that the right products in the correct quantity arrive at 
the right place in a timely manner. This unit is also charged with 
obtaining the best possible process for the highest-quality products for 
distribution and use among the respective organizations within the 
pooled procurement system. The functions of the CPA include 
quantification exercises, selecting procurement and ordering methods; 
prequalifying suppliers and products based on specified standards; 
managing the tender process, establishing contract terms; assuring 
quality of medicines; obtaining best prices and ensuring that suppliers 
adhere to contract terms. In the empirical literature review, some of the 
workings of managing and organizing procurement are restricted 
tendering system and general adjudication of tender processes; limitation 
of procuring only registered products. Some cross cutting supporting 
issues are financial and technical support and favourable legislations and 










CHAPTER 3: RESEARCH METHODOLOGY  
 
3.1 Design 
The study employed a mixed methods research design. There was both 
quantitative and qualitative data collection in the study.  
 
3.2 Population and Sampling 
This was a census survey; the study thus entailed sampling the universe of all 
key stakeholders involved in the EAPPM process. This therefore ruled out 
application of a specific sampling design and technique. A census survey was 
used since the population of 18 was small and the study aimed to reach all the 
previous and current steering committee members of the EAPPM.  Population 
census is unique in that it provides the possibility of examining small and 
special population groups, and acquiring information on small units. The 
census approach is justified since according to Field (2006) results obtained 
from a census are likely to be more representative, accurate and reliable than 
results obtained from a population sample and thus census assists in 
generalization of research findings. Census provides a true measure of the 
population since there is no sampling error and more detailed information 
about the study problem within the population is likely to be gathered 
(Sekaran & Bougie 2010).  
 
The population was stratified into two groups i.e. CEOs and TWG members. 
There were five CEOs and thirteen TWG members. The CEOs were from 
BUFMAR, JMS, MEDS, MEMS and EPN while the TWG members comprised 
of representatives from each of these five organizations. One CEO and two 
TWG members were no longer working with any of the MSOs or EPN at the 
time of data collection.  
 
3.3 Data Collection Methods 
3.3.1 Documents review 
Data was collected by analyzing written reports and minutes of meetings 
of the steering committee in the course of implementing the pooled 
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procurement intervention. The documents that were analyzed are listed 
in Appendix 1. This data collection approach was used to gather data for 
all research questions. Document analysis is a systematic procedure for 
reviewing or evaluating documents—both printed and electronic 
(computer-based and Internet-transmitted) material. It requires that data 
be examined and interpreted in order to elicit meaning, gain 
understanding, and develop empirical knowledge (Corbin & Strauss, 
2008). Document analysis is used in combination with other qualitative 
research methods as a means of triangulation—‘the combination of 
methodologies in the study of the same phenomenon’ (Denzin, 1970). In 
this study, data was drawn from multiple sources of evidence with the 
aim of seeking convergence and corroboration through different data 
sources and methods. 
 
3.3.2 Questionnaires 
Data was collected by use of a questionnaire, administered via electronic 
mail (e-mail) and face-to-face for stakeholders that could be physically 
reached. The questionnaire contained both closed and open-ended 
questions - Refer to Appendix 2. The questionnaire data collection 
approach was used to gather data for all research questions. 
Questionnaires are used as data collection instruments because, 
according to Dempsey (2003), they allow respondents to give much of 
their opinions pertaining to the researched problem. Besides, according 
to Kothari (2003), the information obtained from questionnaires is free 
from bias and researchers influence and thus accurate and valid data is 
gathered.  
 
3.3.3 Focus group discussions and interviews 
A focus group discussion (FGD) and face-to-face interviews were held 
depending on the availability of the study participants. These utilized a 
topic guide - see Appendix 3 - to explore in-depth the attitudes, 
perceptions, challenges and experiences of the steering committee 
members on the implementation of the pooled procurement intervention. 
FGDs and interviews were used to gather data for the research question 
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on how procurement of products was managed and organized in the 
implementation of the EAPPM. Focus group discussions were selected to 
complement the quantitative approach to the study. The aim was to 
obtain the context, in terms of implementing the EAPPM intervention 
that was going to be difficult to obtain quantitatively through 
questionnaires and also to determine consensus on the preliminary 
insights on the research questions (Gibbs, 1997).  
 
Interviews were held for participants who were not able to attend the 
focused group discussion. An interview is a purposeful discussion 
between a researcher and a participant that can help gather valid and 
reliable data that is relevant to the research objectives (Kahn and Cannel, 
1957). 
 
3.4 Data Analysis 
Data from documents was analyzed using content and thematic analysis 
approaches. Content analysis is the process of organizing information into 
categories related to the central questions of the research (Bowen, 2009). 
Content analysis was used to data for objectives (a), (b), (c) and (d). The 
relevance of documents to the research problem and purpose were 
determined. Besides it was ascertained that the content of the documents were 
in line with the conceptual framework of the study. Pertinent information in 
line with the research objectives were elicited from the documents.  
 
Thematic analysis was used for analyzing data for objective (e). Thematic 
analysis is a form of pattern recognition within data, with emerging themes 
becoming categories for analysis (Fereday & Muir-Cochrane, 2006). The 
process involves careful, more focused re-reading and review of data. Selected 
data is keenly examined, coded and categories constructed, based on the data’s 
characteristics, to uncover themes pertinent to a phenomenon. In the analysis 
of data, objectivity (fair representation of research material) and sensitivity 
(responding to even subtle cues to meaning) in the selection and analysis of 
data was exercised. Patterns, resemblances and regularities in experiences 
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shared by respondents were noted in order to reach conclusions from the 
qualitative data. 
 
3.5 Reliability and Validity 
Reliability refers to the consistence, stability, or dependability of the data. 
Whenever an investigator measures a variable, he or she wants to be sure that 
the measurement provides dependable and consistent results (Cooper & 
Schindler 2003). A reliable measurement is one that if repeated a second time 
gives the same results as it did the first time. Validity refers to the extent to 
which an instrument measures what it’s supposed to measure. Data need not 
only be reliable but also true and accurate. If a measurement is valid, it is also 
reliable (Joppe 2000). The validity and reliability of the data collected and the 
response rate achieved thus depend on the design of the questions and the 
structure of questionnaire. To check the validity and reliability of the 
questionnaire and topic guide questions, they were first reviewed by the 
supervisor to check the design and selection of questions and the layout of the 
questionnaire. Adjustments were made based on feedback from the supervisor. 
 
3.6 Ethical Considerations 
This study was approved by the Strathmore University Ethics Committee. The 
letter of approval is given in Appendix 4.  Before filling the questionnaire, 
approval was sought from the various medicine supply organizations 
explaining the purpose and expected outcomes of the study. In addition, 
participants signed an informed consent document - see Appendix 5. This 
involved communication, in writing, prior to their involvement about the 
purpose of the study. Participation in the study was voluntary and participants 
were at liberty to withdraw at any time in the course of the study. There were 
no incentives for those participating in the study. Participants were assured 






CHAPTER 4: RESEARCH FINDINGS AND DISCUSSIONS  
 
4.1 General Information 
4.1.1 Response rate 
A total of eighteen (18) steering committee members who had been 
involved in the EAPPM were issued with the research questionnaire and 
invited for focused group discussions or individual interviews. A total of 
sixteen (16) personnel filled and returned the questionnaires and 
participated in group discussions and interviews. This was a response 
rate of 88.9%. Table 4.1 below indicates the breakdown of responses in 
terms of number of filled questionnaires, number of participants that 
took part in the focus group discussion and number of individual 
interviews held. 












































      
4.1.2 Category of respondents 
The pie chart below illustrates the category of respondents in the 
research.   
 
Figure 4.1. Category of Respondents 
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From the table above, 3 (19%) CEOs and 13 (81%) TWG members participated 
in this research.  
 
4.1.3 Number of years respondents were members of EAPPM steering 
committee 
           Table 4.2 below illustrates the number of years research 
respondents had been involved in the EAPPM. 
 








1 year or less 3 18.8% 
1 to 2 years 3 18.8% 
2 to 3 years 4 25.0% 
Over 3 years 6 37.5% 
Total 16 100.0% 
 
 
4.2 Stakeholder Engagement 
The results indicate that stakeholders were engaged in the implementation of 
the EAPPM intervention. This begun in the year 2010 with a stakeholders 
meeting that was attended by representatives from local, regional and 
international organizations. These included WHO, MSH and Christian Health 
Association of Ghana (CHAG) among others. The deliberations of the meeting 
focused on the need to establish a pooled procurement and exchange of ideas 
on its feasibility and potential impediments. Subsequent meetings were held 
bi-annually or annually. 
These results demonstrate that stakeholders were identified and engaged at the 
inception of the EAPPM. This finding reinforces the argument by Ghoneim et 
al. (2016) that,  
Engaging stakeholders is an essential step in developing and building a 
streamlined and effective pooled procurement system. The essence of 
pooled procurement is about bringing together different organization 
entities, resources and participants to optimize value and efficiency in the 





4.3 Situation Analysis 
The results show that a situation analysis was conducted in the year 2010 as 
part of the pooled procurement intervention process. This was a survey on 
procurement practices in the church pharmaceutical supply agencies in Kenya, 
Rwanda, Tanzania and Uganda. Data gathered entailed stock turnover, 
contribution of medicines to total stock purchases, medicines with limited 
sources, reliable suppliers, difficult to source medicines, payment terms for 
foreign suppliers, challenges encountered in the procurement of medicines, 
perceived benefits from pooled procurement, internal and external obstacles 
envisaged with pooled procurement, categories of medicines to be considered 
for pooled procurement and preferred organizations to be accepted into the 
pooled procurement initiative.  
 
These results established that a situation analysis was conducted at the 
inception of EAPPM to reveal gaps that the pooled procurement intervention 
was going to address. This is similar to the framework by UNICEF (2016), for 
strengthening public health supply chains, which indicates that when a 
strategic and holistic supply chain strengthening process is began, an analysis 
of the current situation is required to ensure that all stakeholders agree on the 
key issues and performance gaps. Establishing a pooled procurement 
mechanism for health products is an aspect of strengthening the procurement 
phase of a health supply chain cycle that ultimately enhances access to 
medicines.   
  
4.4 Consensus Building and Implementation Planning 
The results demonstrate that an EAPPM implementation plan was mutually 
developed by stakeholders over a couple of meetings. Consensus was 
generated on the categories of health products to be included in the initiative 
e.g. hard to source products; products with high consumption rates; 
pharmaceuticals (insulin, oxytocin, analgesics, antibiotics, antineoplastics); 
non-pharmaceuticals (gloves, syringes, gauze rolls and intravenous fluids); 




The results of this study found that consensus building and implementation 
planning featured at the inception of EAPPM. Consensus was generated on the 
categories of health products to be included in the EAPPM, financial resources 
for managing EAPPM, selection and appointment of TWG members and 
development of annual work plans. This is similar to the study by Ghoneim et 
al., 2016 that indicated that, “Stakeholders must have an organized and 
collaborative approach to planning implementation in the establishment of 
pooled procurement systems.” UNICEF (2016) also found that, “an essential 
piece for comprehensive system strengthening and capacity development is 
agreement between all the partners on a strategy.” 
 
4.5 Central Procurement Agency or Secretariat  
The results revealed that the organization, EPN was appointed as central the 
procurement agency or secretariat as part of the EAPPM intervention. Roles 
and responsibilities for each procurement process were defined but 
procurement standard operating procedures were not developed.  
 
This outcome of the research is supported by (Ghoneim et al., 2016) that in the 
establishment of a pooled procurement mechanism, stakeholders need to 
decide on the objective and overall mandate of a central procurement agency. 
Similarly, the (Centre for Pharmaceutical Management, 2002) found that “A 
strong central authority that ensures financial mechanisms are sound and 
adequately enforced plays a crucial role. The absence of such an authority 
contributed to the failure of FORMED.”  
 
4.6 Managing and organizing procurement 
The results indicate that procurement of products in implementing the EAPPM 
intervention was coordinated by EPN. Assistance was offered by members of 
the TWG where country specific procurement related information was 
required. The procurement processes involved quantification and forecasting; 
harmonization of products; pre-qualification of suppliers; tendering approach 
and adjudication; price negotiations; monitoring and adherence to contract 
terms; monitoring order status;  receiving products; paying suppliers; 
reporting, monitoring and evaluation. According to Ghoneim et al, (2016), 
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“The procurement agency plays a vital role in managing and 
organizing the procurement processes which revolve around ensuring 
that the right products in the correct quantity arrive at the right place in 
a timely manner within the pooled procurement system”. 
 
4.6.1 Challenges encountered in managing and organizing pooled 
procurement 
The study revealed that there were multiple challenges with the 
procurement processes. These have been categorized as major, moderate 
and minor based on the extent of direct impact on affordability, 
availability and quality of essential medicines – the ultimate goals of the 
EAPPM. See Appendix 6 for the complete list of challenges the study 
revealed. The major challenges were conflicting legislations and 
regulations for health products across the East African countries and 
limited financial resources for procuring health products. The moderate 
challenges were quantification and forecasting; pre-qualification of 
suppliers; tendering approach and adjudication; price negotiations; 
monitoring and adherence to contract terms; monitoring order status;  
receiving products and reporting, monitoring and evaluation. The only 
minor challenge was harmonization of products.  
a) Legislation and regulation in East Africa 
This research revealed that legislations and regulations of health 
products in member East African countries were heterogeneous and 
were impeding EAPPM’s success. Firstly, there was very few health 
products registered in all the four or at least three countries. 
Secondly, taxes, duties and freight clearance charges differed from 
one country to another leading to inequitable cost savings among 
MSOs. For instance, in Kenya, “value added tax (VAT) on sterile and 
non-sterile gloves hindered bidders from offering unified prices for all 
MSOs” says one TWG member. Thirdly, specifications for gloves 
and syringes varied from one country to another leading to tender 
awards and supply of different products with different quality 
standards and prices to different countries. This reduced pooled 
quantities and eliminated the benefits of economies of scale. Worse 
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still, gloves from a pre-qualified supplier failed quality tests in 
Uganda and reduced supplier confidence among the rest of the 
MSOs. Finally, information on the validity of a product’s 
registration status was not always available. The registration status 
of some products became invalid during importation processes and 
before import permits were granted by national authorities. This led 
to prolonged lead times. 
 
The challenge of legislation and regulation in East Africa is 
similar to that faced by ACAME regional pooled procurement 
program as established by Center for Pharmaceutical Management, 
(2002). It found that drug registration in member countries differed 
and unfortunately, tender documents had not adequately clarified 
controlling rules when drug registration regulations in the various 
countries differed. Besides, according to (ACAME and 
WHO/AFRO 1999b),  
“Because of its system of registration of products and it’s 
very strict policy on authorizing new pharmaceutical 
products, Morocco had never extensively participated in bulk 
purchasing and had never purchased or imported more than 
5 percent of its drug needs through bulk purchasing.” 
 
Bailey (1999) also observes that, 
The most common constraint on international procurement is 
drug registration. Countries with drug registration systems 
normally require that all drugs purchased through public 
tender be registered locally. Both restricted and open tenders 
can be limited to products registered in the purchasing 
country. This requirement may basically eliminate 
international procurement if the registration process is 
complicated and time-consuming. 
 
The research also revealed that the long turnaround time of 
processing tax exemption certificates contributed to the challenge of 
37 
 
long lead times.  In the FORMED pooled procurement program, 
one of the reasons for its failure was that originally, the lead time 
was set at four months, but in reality it became five to seven months 
(and more than a year in one case when the orders were misfiled) 
(Rankin 1991b). 
 
b) Financial resources 
With regard to financial resources for procuring health products, 
the results revealed that MSOs were paying suppliers in good time 
for the products they procure. Since prices of pharmaceuticals were 
generally high, MSOs with financial constraints were often limited 
in terms of product volumes they could purchase. Three out of the 
four participating MSOs were meeting their financial obligations to 
the secretariat. They were however all able to meet travel and 
accommodation costs for their TWG members to attend tender 
evaluation meetings in Kenya. 
 
WHO (2007) indicates that one of the main challenges related to 
financing and financial arrangements of regional pooled 
procurement is inadequate total financing for procuring essential 
medicines. The (Centre for Pharmaceutical Management, 2002) also 
found that lack of payment to the revolving fund had been 
attributed to as the main reason for FORMED’s failure. The donor-
funded revolving fund absorbed the costs that were not 
reimbursed, which drained the fund account.  
 
Financing of pooled procurements must therefore be sustainable, 
predictable and timely and the administrative costs of a pooled 
procurement mechanism have to be offset by the savings on drug 
purchases (EAC, 2007). 
 
With regard to paying suppliers, the research established that some 
MSOs were delaying payments to suppliers. Late payment is a 
disincentive for suppliers. Burnett (2001) stated that an important 
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element in OECS/PPS’s initial success in reducing the costs of 
pharmaceuticals was the ability to pay suppliers promptly in 
foreign exchange within 42 days of receipt of goods. The reputation 
for prompt payment that OECS/PPS established initially had been 
tarnished in because some of OECS countries were slow in 
reimbursing the country drug accounts due to economic challenges. 
Late payments had resulted in several suppliers withholding 
shipments to both defaulting and non-defaulting countries (Centre 
for Pharmaceutical Management, 2002). 
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CHAPTER 5: CONCLUSIONS AND RECOMMENDATIONS 
 
5.1 Introduction 
This study sought to assess how the East African pooled procurement 
intervention was implemented, challenges encountered and key strategies for 
the realization of intended outcomes. The objectives of the study were to 
determine if stakeholders were engaged in the implementation of the EAPPM 
intervention; to determine if a situation analysis was conducted in the 
implementation of the EAPPM intervention; to find out if an EAPPM 
implementation plan was mutually developed by stakeholders; to find out if a 
central procurement agency or secretariat was established in the 
implementation of the EAPPM intervention and to establish how procurement 
of products was managed in the implementation of the EAPPM intervention. 
 
5.2 Conclusions 
From the research findings it can be concluded that: 
5.2.1 Stakeholder engagement 
Stakeholders were engaged in the implementation of the EAPPM 
intervention. Various stakeholders were identified, a unanimous decision 
to establish the EAPPM was made and subsequent meetings were held to 
deliberate on implementation aspects. 
 
5.2.2 Situation analysis 
A structured situation analysis was conducted in the implementation of 
the EAPPM. The situation analysis was conducted to capture 
procurement related gaps that the pooled procurement intervention was 
going to address, obstacles envisaged with pooled procurement 
intervention, and organizations to be accepted into the pooled 







5.2.3 Consensus building and implementation 
An EAPPM implementation plan was mutually developed by 
stakeholders over a couple of meetings. Consensus was generated on the 
categories of health products to be included in the initiative, work plans 
and procurement processes.  
 
5.2.4 Central procurement agency or secretariat 
A CPA was established in the implementation of the EAPPM. EPN was 
appointed as the CPA of the EAPPM intervention and its mandate was 
clearly made.  
 
5.2.5 Managing and organizing procurement 
The procurement of products managed in the implementation of the 
EAPPM intervention was coordinated by the Secretariat assisted by 
members of the TWG. The procurement processes involved 
quantification and forecasting; harmonization of products; pre-
qualification of suppliers; tendering approach and adjudication; price 
negotiations; monitoring and adherence to contract terms; monitoring 
order status; receiving products; paying suppliers; reporting, monitoring 
and evaluation. Several challenges were noted with these processes. 
These were major, moderate or minor depending on the weight of their 
direct impact on the affordability, availability and quality of health 
products.   
 
5.2.6 Challenges faced by the EAPPM 
Two major challenges were noted in implementing the EAPPM. These 
were conflicting country legislation and regulations of health products 
and limited financial resources for procuring health products and 
meeting administrative costs 
 
5.3 Research limitations 
Information collected from the research participants was limited to their 





Based on the challenges faced by the EAPPM, as revealed by research findings, 
it is recommended that: 
5.4.1 Heterogeneous legislation and regulations 
a) The fourth model of pooled procurement also known as central 
contracting is applied to products with high consumption rates that 
either do not require registration or are registered in all participating 
countries and have similar quality specifications. In the fourth model 
of pooled procurement, member countries jointly conduct tenders 
and award contracts through a representative organization or 
secretariat.  
b) The third model of pooled procurement also known as group 
contracting is applied to all other categories of products irrespective 
of pooled quantities, quality specifications and registration status.  
 
5.4.2 Financial resources 
A revolving drug fund (RDF) be established to finance MSOs that are not 
financially stable. In a RDF a sum of money (contributed by the 
government, donors or the community) is used to purchase an initial 
stock of essential and commonly used medicines to be sold, ideally at a 
price sufficient to replace the stock of medicines and ensure a continuous 
supply (MSH, 2012). This approach will ensure affordable and 
sustainable supply of quality assured essential medicines and medical 
supplies.  
 
5.4.3 Moderate and minor challenges 
A continuous quality improvement (CQI) system should be adopted for 
the EAPPM through reporting, monitoring and evaluation. CQI is a 
quality management philosophy that encourages everyone in an organization, 
including board members, volunteers, and employees, to continuously ask 
what can be done better. It builds on existing quality management approaches 
such as total quality management (TQM), Lean, and Six Sigma, but emphasizes 
that internal and external customer satisfaction is paramount, and that 
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APPENDIX 1 - DOCUMENTS REVIEWED 
 
  
Name of document  
 
1. 
EAC Pooled Procurement, Minutes of the CEOs and TWG meeting 




The EAC Pooled Procurement Project, Terms of Reference, 2016 
 
3. 
The East Africa Pooled Procurement Project, The Project 
Performance and Status Report, January 2015. 
 
4. 
EAC Pooled Procurement, Memorandum of Understanding, 
Multilateral Co-operation Agreement, 2013.  
 
5. 
EAC Pooled Procurement, Technical Working Group, Terms of 
Reference, 2013.  
 
6. 
Report of the CEOs Pooled Procurement Meeting held on 2nd 
September 2011at Red Court Hotel, Nairobi, Kenya. 
 
7. 
Survey of Procurement in Six Church Pharmaceutical Supply 
Agencies in the Ecumenical Pharmaceutical Network, 2010. 
 
8. 
Pooled Procurement of Medicines by Church Pharmaceutical 
Supply Agencies, Meeting Report, Dar es Salaam, Tanzania, 12th to 

































APPENDIX 2 - QUESTIONNAIRE  
 
 




1. Medicine supply organization  
 
 BUFMAR, Rwanda 
 JMS, Uganda 
 MEDS, Kenya 
 MEMS, Tanzania 
 
Respondent information  
 
2. Current position in the organization  
 
 Chief Executive Officer  
 Member, Technical Working Group 
 Other: ________________________________ 
 
3. Number of years involved in EAC pooled 
procurement mechanism  
 
 More than 3 years  
 2 to 3 years  
 1 to 2 years  




Section 2 – East African Community Pooled Procurement Mechanism Challenges and Solutions  
A. Stakeholder Engagement  
(Engaging stakeholders is for developing and building a streamlined and effective pooled procurement 
system. This brings together different organization entities, resources and participants to optimize value 
and efficiency in the health commodities supply chain) 
 
4. All key stakeholders (MSOs, procurement agencies, pharmaceutical suppliers) were involved in the 
initiation of the EAPPM. 
 Strongly agree     Agree     Undecided     Disagree     Strongly disagree 
 
5. Identified stakeholders discussed and agreed on the pooled procurement option to be adopted 
(Informed buying; coordinated informed buying, group contracting and central contracting). 
 Strongly agree     Agree     Undecided     Disagree     Strongly disagree 
 
6. The objectives, intended benefits and primary concerns for collaboration were determined and 
documented.  
 Strongly agree     Agree     Undecided     Disagree     Strongly disagree 
 
7. A strategic plan was developed for the management and implementation of the selected pooled 
procurement model including creating a technical working group or a central unit for co-ordination. 
 True     False     I don’t know 
 
8. The roles and responsibilities of the Chief Executive’s Committee and the Technical Working Group in 
the implementation of the EAPPM are clearly defined with performance indicators. 









B. Situation Analysis  
(A situation analysis ensures that all stakeholders are in agreement about what the current issues are and 
where performance gaps are in terms of procurement and availability of essential health products) 
 
9. A structured situation analysis was conducted to reveal current practices and gaps that would inform 
establishment of the pooled procurement mechanism?  
 Strongly agree     Agree     Undecided     Disagree     Strongly disagree 
 
10. The EAPPM was established to address the following gaps: (Mark all that apply) 
 
 Inadequate financing for products     Inadequate human resource     Weak procurement processes 
         
  High cost of essential health commodities     Poor lead times     Stock-outs for health commodities 
         
   Others____________________         
 
11. List the gaps, if any, that the pooled procurement mechanism has addressed to a “great extent”. 
 
12. List the gaps, if any, that the pooled procurement mechanism has thus far addressed to “some 
degree”. 
 
13. List the gaps, if any, that the pooled procurement mechanism has thus far addressed to “a minimal 
extent” 
 




C. Implementation Planning (Consensus building is a process of seeking unanimous agreement. It involves a 
good-faith effort to meet the interests of all stakeholders.) 
 
15. The categories of health products to be included in the pooled procurement mechanism were discussed 
and agreed upon. 
 Strongly agree     Agree     Undecided     Disagree     Strongly disagree 
 
16. Financial resources for managing the PPM were indentified and are available when needed. 
 Strongly agree     Agree     Undecided     Disagree     Strongly disagree 
 
17. The knowledge, skills and abilities of the technical working group members was considered before 
appointment to the team and correspond with the different processes of procurement and 
coordination. 
 Strongly agree     Agree     Undecided     Disagree     Strongly disagree 
 
18. The EAPPM has annual work plans with outputs, responsibilities, deadlines, budget requirements and 
SMART performance objectives that are monitored.  
 Strongly agree     Agree     Undecided     Disagree     Strongly disagree 
 
19. A signed memorandum of understanding exists between member MSOs and the coordinating 
organization (EPN). 
 Yes     No     I don’t know    
 
20. If you are a member of the TWG, indicate which phrase below applies to you. 
 I was issued with an appointment letter prior to joining the TWG. 
 I was issued with an appointment letter and terms of reference prior to joining the TWG. 





D. Setting Up a Central Procurement Agency  
 
21. A procurement method was agreed upon at the inception of the EAPPM. Procurement  methods 
include open tender, restricted tender, competitive negotiation and direct procurement) 
 
 Yes     No     I don’t know 
 
22. Roles and responsible persons for each procurement process are clearly defined. 
 
 Yes     No     I don’t know 
 
23. Standard operating procedures are in place for each procurement related process. 
 




E. Managing and Organizing Procurement  
 
24. Please indicate procurement related components that have gaps and need to be addressed. Write a 
concise description of the gap/challenge and propose solutions. Consider availability of standard 
operating procedures, required human resource for each component, availability of work plans, tools 













 Harmonization of products 
and forecasts  
  
 
 Pre-qualification of suppliers  
  
 




 Price negotiations  
  
 
 Monitoring adherence to 
contract terms  
  
 
 Monitoring order status  
  
 
 Receiving products  
  
 
 Paying suppliers  
  
 








APPENDIX 3 – TOPIC GUIDE 
 
 
Topic Guide (Qualitative) 
 
 
1. Shared executive leadership commitment  
 Do you think there has been shared executive commitment in the 
implementation of EAPPM? Indicators of commitment or non-
commitment? 
 What are the financial and non-financial benefits that the EAPPM has 
realized? Have these influenced executive leadership commitment? 
 How should non-commitment be spurred, if any? 
 
2. Legislation and regulation in East Africa 
 How have the following been handled in the EAPPM? (Registration of 
health products; Taxes and duties; Freight and clearance; Quality 
standards)  
 Any challenges encountered? 
 Any recommendations to enhance these processes? 
 
3. Financial resources  
 Any financial concerns with regard to procuring of health products? 
 How have costs for managing the pooled procurement been handled? Any 
challenges? Any future recommendations?  
 
4. Capacity building  
 Has the need for capacity building on pooled procurement for TWG 
members ever been identified? 
 Have capacity building sessions on pooled procurement been conducted 
since inception of the EAPPM? 
 In what areas do you think there is need for capacity building? 
 
5. Harmonization  
 What components of the EAPPM have required harmonization? 
 How have these been handled? Any challenges? 
































APPENDIX 5 – PARTICIPANT’S CONSENT FORM  
 
SECTION 1: INFORMATION SHEET  
1.1 Investigator: Dr. Collins D. P. Jaguga 
1.2 Institutional affiliation: Strathmore Business School (SBS), Strathmore University, 
Kenya  
 
SECTION 2: INFORMATION SHEET–THE STUDY  
2.1 Why is this study being carried out? 
This study is being carried out to assess how the East African Pooled Procurement 
Mechanism (EAPPM) was implemented since inception, an exploration of challenges 
encountered and to determine the appropriate next steps to achieve sustainable success 
and ultimately better access to medicines in the East African region. 
 
2.2 Do I have to take part? 
No. Taking part in this study is entirely optional and the decision rests only with you. 
If you decide to take part, you will be asked to complete a questionnaire to get 
information on how EAPPM was established, operationalized, challenges encountered 
and key success factors for sustainable success. If you are not able to answer all the 
questions successfully the first time, you may be asked to sit through another 
informational session after which you may be asked to answer the questions a second 
time. You are free to decline to take part in the study at any time without giving any 
reasons.  
 
2.3 Who is eligible to take part in this study?  
 Chief Executive Officers of the organizations involved in the EAPPM. 
 Members of the technical working group of the EAPPM. 
 
2.4 Who is not eligible to take part in this study?  
 Those not defined in the criteria in 2.3 above. 
 
2.5 What will taking part in this study involve for me? 
You will be approached by the researcher and requested to take part in the study. If 
you are satisfied that you fully understand the goals behind this study, you will be 
asked to sign this informed consent form and then offered the questionnaire to 
complete. You will also be asked to take part in a focused group discussion to elicit 
detailed information on the research topic. 
 
2.6 Are there any risks or dangers in taking part in this study? 
There are no risks in taking part in this study. All the information you provide will be 
treated as confidential and will not be used in any way without your express 
permission. 
  
2.7 Are there any benefits of taking part in this study? 
The information will be used to improve pooled procurement of essential medicines in 




2.8 What will happen to me if I refuse to take part in this study? 
Participation in this study is entirely voluntary. Even if you decide to take part at first 





2.9 Who will have access to my information during this research? 
All research records will be stored in securely locked cabinets. That information may 
be transcribed into our database but this will be sufficiently encrypted and password 
protected. Only the people who are closely concerned with this study will have access 
to your information. All your information will be kept confidential.  
 
2.10 Who can I contact in case I have further questions? 
You can contact me, Dr. Collins D. P. Jaguga, at SBS, or by e-mail 
cjaguga@epnetwork.org, or by phone +254-734-964-644 / 705-302552. You can also 
contact my supervisor, Dr. Francis Wafula, at the Strathmore Business School, 
Nairobi, or by e-mail fwafula@strathmore.edu or by phone +254-722-679-467. 
 
If you want to ask someone independent anything about this research please contact:  
The Secretary–Strathmore University Institutional Ethics Review Board, P. O. BOX 59857, 
00200, Nairobi, email ethicsreview@strathmore.edu Tel number: +254 703 034 375  
 
I, ______________________________, have had the study explained to me. I have understood 
all that I have read and have had explained to me and had my questions answered 
satisfactorily. I understand that I can change my mind at any stage.  
 
Please tick the boxes that apply to you;  
 
Participation in the research study  
 




Participant’s Signature:  
 
_____________________________________  
Date: ______/_______/_________  
                                                                                                DD / MM / YEAR  
 






Time: ______ /_______  
(Please print name)                  HR / MN  
 
I, Dr. Collins D. P. Jaguga certify that I have followed the SOP for this study and have 
explained the study information to the study participant named above, and that s/he has 
understood the nature and the purpose of the study and consents to the participation in the 
study. S/he has been given opportunity to ask questions which have been answered 
satisfactorily. 
 
Investigator’s Signature:  
 
___________________________________  
Date: ______/_______/_________  
                                                                                                                         DD / MM / YEAR  
 





Time: ______ /_______  






APPENDIX 6 - CHALLENGES ENCOUTERED BY EAST AFRICAN 















a) Since forecasting is largely dependent on historic 
consumption data, which may not be fully accurate, 
some MSOs end up not placing orders for projected 
quantities leading to displeased suppliers. 
b) Q&F is not harmonized. 
c) Inaccurate quantification of heath products since 
health facilities inconsistently order products from 





of products and 
forecasts  
 
a) Conversion of product descriptions from French to 
English often leads to incorrect product 
descriptions. 
b) Poor prediction of delays. 
c) The product list is too long and might not be 
attractive to potential bidders. 
d) Some MSOs seem attached to old suppliers for 
certain products despite potential benefits with new 
suppliers. 
e) MSOs do not adhere to set deadlines in collating 
and submitting information on forecasts to the 
secretariat. 
f) Product specifications are not fully harmonized; the 





of suppliers  
 
a) Use of prequalified suppliers list from different 
MSOs yet each organization has a different 
prequalification procedure. 
b) Limited choice of suppliers thus reduced 
competitiveness in prices offered. 
c) MSOs with the wherewithal to conduct supplier 








a) Restricted tendering gives quick results but might 
not necessarily give the most competitive offers. 
May also be considered unfair since only previous 
suppliers participate in the tender. 
b) The evaluation of tender documents is a manual 
process and is not free from errors. 
c) Bidders often raise several questions during the 
tender open period, possibly implying that certain 









CHALLENGES ENCOUTERED BY EAST AFRICAN POOLED 
















a) Negotiated prices are still not as desired given the 
large pooled quantities of products. 
b) Fluctuating prices of products. 
c) EPN might not be well placed to negotiate for price 
reductions since they are not armed with market 
prices. MSOs might be able to obtain better prices 
individually than under pooled procurement thus 
watering down the intended benefits. 
d) MSOs are not involved in price reduction 
negotiations.  
e) Poor negotiation approach. 
f) The impact of price negotiations is not being felt. 







contract terms  
 
a) Occasionally, either suppliers or MSOs breach 
contract terms. Often realized too late e.g. delivery 
of supplies of a different quality than that awarded.  
b) EPN is a principal signatory in the EAPPM contracts 
yet MSOs have authority to cancel contracts even if 





order status  
 
a) There is no system for monitoring the status for 
orders. 
b) It’s challenging for EPN to monitor the status of 
orders since they are not the users. 
















a) Delays by suppliers in acknowledging receipt of 
payment by MSOs. 
b) Some MSOs delay payments to suppliers.  








a) No reporting, poor monitoring and evaluation. 
b) Monitoring and evaluating performance is based on 
e-mail communications through feedback from 
member organizations 
c) There are quarterly briefs for CEOs but limited 








a) Very few products registered in four or three 
countries thus reducing pooled quantities.  






CHALLENGES ENCOUTERED BY EAST AFRICAN POOLED 















a) Non-payment of annual administrative fees to 
secretariat by one MSO. 








a) Contracts management skills  
b) Negotiation skills  
c) International procurement procedures  
d) Evaluation of non-pharmaceuticals  









































APPENDIX 7 – SIGNED PARTICIPANT’S CONSENT FORMS 
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